证券代码：300314 证券简称：戴维医疗 公告编号：2025-036 宁波戴维医疗器械股份有限公司 关于全资子公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁波 维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得由浙江省 药品监督管理局颁发的1项《受理通知书》，受理号为：械受20254020683。 具体情况如下： | 序号 | 产品名称 | 注册分类 | | 临床用途 | | --- | --- | --- | --- | --- | | 1 | 一次性使用胃管 | II | 类 | 插入胃部，排空、清洗、灌注用。 | 维尔凯迪开发的一次性使用胃管与相关的肠胃给药器配合或靠液体重力， 在导管内形成正压或负压。胃管经食道插入至远端胃窦，可用于气体、液体 或流质营养的输入、排（吸）液等，还可用于胃部冲洗。宝塔接头有扣盖， 有利于保持清洁。外壁带有数字刻度和管壁带有 X 光显影标记线，两者均可 有效控制产品的使用长度，助力医疗团队为患者制定个性化治疗方案，推动 ...

Company Overview - David Medical's closing price on July 4 was 12.77 yuan, down 1.01%, with a rolling PE ratio of 88.15 times and a total market value of 3.678 billion yuan [1] - The company ranks 105th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1] Financial Performance - For Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year [2] - The sales gross margin was reported at 57.13% [2] Shareholding Structure - As of the Q1 2025 report, there are 2 institutional investors holding shares in David Medical, including 1 QFII and 1 insurance company, with a total holding of 1.2529 million shares valued at 1.5 million yuan [1] Product Portfolio - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, including incubators, radiant warmers, jaundice treatment devices, and various monitoring and therapeutic equipment [1] Industry Recognition - The company has been recognized as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology and has received multiple honors, including "Famous Brand in Zhejiang Province" and "AAA Credit Rating Enterprise" [1]

| 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 医用电动吸引 | 浙械注准 | 2031.1.4 | Ⅱ类 | 产品与医用导管 | | | 器 | 20162140332 | | | 配套使用，供临床 | | | | | | | 吸取新生儿粘液 | | | | | | | 及新生儿羊水之 | | | | | | | 用。 | 本次延续注册的完成，使得公司可以继续生产和销售医用电动吸引器， 对公司未来经营将产生积极影响。上述产品的实际销售情况取决于未来市 场推广效果，公司目前尚无法预测其对公司未来业绩的影响，敬请投资者 注意投资风险。 特此公告。 宁波戴维医疗器械股份有限公司 证券代码：300314 证券简称：戴维医疗 公告编号：2025-035 宁波戴维医疗器械股份有限公司 关于公司部分医疗器械产品完成延续注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the latest quarter [1][2] - As of June 30, David Medical's stock closed at 12.7 yuan, with a PE ratio of 87.66, which is significantly higher than the industry average of 50.61 [1][2] - The company has a total market capitalization of 36.58 billion yuan, ranking 105th in the medical device industry based on PE ratio [1][2] Group 2 - In the first quarter of 2025, David Medical reported an operating income of 1.21 billion yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% [2] - The company's sales gross margin stands at 57.13%, indicating a relatively high profitability despite the decline in revenue and profit [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators and neonatal monitoring devices [1]

Core Viewpoint - David Medical (300314) announced that its wholly-owned subsidiary, Weierkaidi, has recently obtained three acceptance notices from the Zhejiang Provincial Drug Administration for new medical devices [1] Group 1: Product Details - The acceptance numbers are 20254019912, 20254019913, and 20254019722 [1] - The products include a disposable lung nodule localization puncture needle, a disposable electronic ureteral renal pelvis endoscope catheter, and a portable electronic endoscope image processor [1] - All registered products are classified as Class II medical devices [1] Group 2: Financial Impact - The acceptance of these product registration applications will not have an impact on the company's recent performance [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-034 宁波戴维医疗器械股份有限公司 关于全资子公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁波 维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得由浙江省 药品监督管理局颁发的3项《受理通知书》，受理号为：械受20254019912、 械受20254019913、械受20254019722。具体情况如下： | 序号 | 产品名称 | 注册分 类 | | 临床用途 | | --- | --- | --- | --- | --- | | 1 | | | | 本产品适用于肺结节患者接受胸腔镜手术前的 CT | | | 一次性使用肺结节定 位穿刺针 | II | 类 | 引导下的肺结节定位，带线锚钩留置体内时间小于 | | | | | | 24 小时。 | | 2 | 一次性使用电子输尿 管肾盂内窥镜导管 | II | 类 | 本产品与本公司电子内窥镜图像处理器配合使用， 通过视频监视器提供影像，用 ...

Group 1 - Xiansheng Pharmaceutical announced that its insomnia treatment drug Daridorexant (brand name: Kewiko®) has been approved for marketing in China, enhancing patient access and supporting long-term use [1] - HAP Pharmaceutical entered a global strategic collaboration with Otsuka Pharmaceutical to develop a BCMAxCD3 bispecific T-cell engager, receiving an upfront payment of $47 million and potential additional payments up to $623 million based on future milestones [1] - Baotai announced a licensing agreement with Stein for the commercialization rights of BAT2406 (Dupilumab) in Latin America, with total upfront and milestone payments potentially reaching $10 million [1] Group 2 - David Medical received a medical device registration certificate for its electric stretcher, which offers significant advantages over traditional manual devices, improving operational efficiency and reducing the burden on healthcare personnel [2] - Hanyu Pharmaceutical's subsidiary received approval for the listing of its active pharmaceutical ingredient Acetate Degarelix, which is used to treat advanced prostate cancer [3] - China Traditional Chinese Medicine reported that its innovative TCM drug Yushudapin's registration application has been accepted, showing significant efficacy in improving early symptoms of depressive disorders [4]

Core Viewpoint - David Medical (300314) has received the Medical Device Registration Certificate from the Zhejiang Provincial Drug Administration for its new product, the electric stretcher, which will enhance the company's pre-hospital emergency and in-hospital transfer solutions [1] Group 1 - The acquisition of the electric stretcher will fill a product gap in the emergency equipment sector for the company [1] - This new product will enrich the company's product line and improve its core competitiveness [1] - The positive impact on the company's future operating results is anticipated due to this development [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-033 宁波戴维医疗器械股份有限公司 关于新产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，宁波戴维医疗器械股份有限公司（以下简称"公司"）的新产 品电动担架车获得了浙江省药品监督管理局颁发的《医疗器械注册证》， 具体如下： 一、医疗器械注册证的具体情况 产品名称：电动担架车 型号、规格：DJ-100、DJ-100A、DJ-100B、DJ-100C 注册证编号：浙械注准20252151458 适用范围：用于医疗机构运送、移动患者用。 二、新产品的市场状况 随着医疗科技革新与临床需求升级，智能化急救设备已成为现代医疗 体系的重要支撑。电动液压担架车相较于传统手推式设备，在临床场景中 展现出显著优势，其电动液压升降系统能够实现平稳、快速的升降操作， 减少了传统手动操作中可能出现的颠簸和不适，同时也减少医护人员手动 操作的强度，减轻医护负担。该产品医疗器械注册证的取得将完善公司院 前急救-院内转运全链路解决方案，填补公司在急救设备领域的产品空白。 三、对公司的影响 以 ...

本公司2024年年度权益分派方案为：以公司现有总股本288,000,000 股为基数，向全体股东每10股派0.870000元人民币现金（含税；扣税后， 通过深股通持有股份的香港市场投资者、境外机构（含QFII、RQFII）以及 持有首发前限售股的个人和证券投资基金每10股派0.783000元；持有首发 后限售股、股权激励限售股及无限售流通股的个人股息红利税实行差别化 税率征收，本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股 期限计算应纳税额【注】；持有首发后限售股、股权激励限售股及无限售 流通股的证券投资基金所涉红利税，对香港投资者持有基金份额部分按10% 征收，对内地投资者持有基金份额部分实行差别化税率征收）。 二、权益分派方案 在分配方案实施前，若公司股本发生变化的，公司将按照"分红总额 不变"的原则，对分配比例进行调整。 生变化。 超过两个月。 证券代码：300314 证券简称：戴维医疗 公告编号：2025-032 宁波戴维医疗器械股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）202 ...